Edition:
United Kingdom

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

22.40USD
6:33pm GMT
Change (% chg)

$0.84 (+3.90%)
Prev Close
$21.56
Open
$21.80
Day's High
$22.51
Day's Low
$21.66
Volume
21,113
Avg. Vol
76,097
52-wk High
$28.62
52-wk Low
$18.67

Latest Key Developments (Source: Significant Developments)

Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Xencor Inc ::XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS.XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018.  Full Article

Xencor posts Q3 loss of $0.33 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Xencor Inc :Xencor reports third quarter 2017 financial results and provides clinical pipeline update.Q3 revenue $7.1 million versus i/b/e/s view $6.3 million.Q3 loss per share $0.33.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Xencor q2 earnings per share $1.13
Tuesday, 2 Aug 2016 

Xencor Inc : Q2 earnings per share $1.13 .Q2 revenue $66 million versus $1.0 million.  Full Article

Xencor provides updates on lead programs, reviews bispecific oncology partnership
Tuesday, 28 Jun 2016 

Xencor Inc : Xencor provides updates on lead programs and reviews bispecific oncology partnership; announces expansion of bispecific oncology pipeline at analyst day . Announced expansion of its pipeline with two new bispecific oncology programs .Remain on track to initiate Phase 1 trials with subcutaneous formulations of both XMAB5871 and XMAB7195 this year.  Full Article

Xencor enteres into collaboration and license agreement with Novartis
Tuesday, 28 Jun 2016 

Xencor Inc : Xencor announces strategic collaboration for bispecific programs, including XMAB 14045 and XMAB 13676 . Has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics . Parties will collaborate and share development costs for worldwide development of XMAB14045 and XMAB13676, with Xencor . Will receive a $150 million upfront payment and is eligible to receive clinical, regulatory and sales milestone payments for successful programs . Says eligible to receive tiered, low double-digit royalties for sales of XMAB14045 and XMAB13676 outside of U.S. . Novartis to receive worldwide rights to co's bispecific technology to develop and commercialize four additional targets selected by Novartis .Says Novartis will receive a worldwide non-exclusive license to use Xencor's XMAB FC technologies in up to ten molecules.  Full Article

Xencor reports complete data results from XmAb7195 phase 1a trial
Wednesday, 18 May 2016 

Xencor : Results of study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. .Xencor reports complete data results from xmab7195 phase 1a trial showing rapid reduction of serum ige in high ige atopic subjects at ats 2016 international conference.  Full Article

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS